Amikacin (BAY416651): Precision Tools for Advanced Antibiotic Resistance Research

Principle Overview: Mechanism and Research Rationale

Amikacin (BAY416651) is a semi-synthetic aminoglycoside antibiotic that plays a pivotal role in antibiotic resistance research and the study of challenging Gram-negative pathogens. By binding to the bacterial 30S ribosomal subunit, it acts as a potent bacterial protein synthesis inhibitor, exerting rapid bactericidal effects—a property that makes it indispensable for dissecting resistance mechanisms in Enterobacteriaceae, including carbapenem-resistant Enterobacter cloacae and Klebsiella pneumoniae (source). Notably, Amikacin is engineered to resist most aminoglycoside-modifying enzymes, though susceptibility to acetylation by AAC (6')-I enzymes can arise in select strains (source: molecular_insights). Its robust aqueous solubility and stability further enhance its utility in reproducible, quantitative workflows.

Step-by-Step Workflow: Applied Experimental Enhancements

Optimizing the use of Amikacin (BAY416651) in laboratory protocols begins with precise preparation and handling. APExBIO supplies Amikacin as a solid, ensuring long-term stability at -20°C. For experimental applications, its water solubility (≥5.86 mg/mL) streamlines preparation of high-concentration stocks—critical for dose-response and time-kill studies (product_spec).

Protocol Parameters

• Preparation of stock solution | 5.86 mg/mL in sterile water | All in vitro antimicrobial assays | Ensures maximal solubility and reproducibility for quantitative assays | product_spec
• Incubation temperature for dissolution | 37°C for 10 minutes or ultrasonic shaking | Preparation of high-concentration working solutions | Accelerates dissolution, avoids DMSO/ethanol insolubility issues | product_spec
• Application concentration in resistance studies | 4–64 µg/mL | MIC determination for K. pneumoniae and E. cloacae | Reflects typical breakpoint and research-relevant dosing for multidrug-resistant strains | workflow_recommendation

For rapid dissolution, briefly warming the solution at 37°C or applying ultrasonic agitation is recommended. Importantly, stock solutions should be freshly prepared, as extended storage may compromise activity (source: product_spec).

Key Innovation from the Reference Study

The landmark study by Montes-Worboys et al. (reference) introduced a transformative workflow: targeted delivery of Amikacin into granulomas using monocyte-derived dendritic cells (DCs) as cellular drug carriers. By conjugating Amikacin to fluorescein isothiocyanate (FITC), researchers tracked intracellular antibiotic uptake and demonstrated that DCs loaded with Amikacin-FITC could home to granulomas in a murine Mycobacterium avium model. This approach achieved high local antibiotic concentrations at the infection site with minimal systemic exposure, mitigating toxicity risks.

Practical translation: For researchers studying intracellular pathogens or tissue-trapped bacteria (e.g., nontuberculous mycobacteria), leveraging DC-based delivery allows site-directed antibiotic release. Quantitative fluorescence tracking (using FITC-conjugated Amikacin) can validate cellular uptake and biodistribution, supporting detailed pharmacodynamic studies. This method provides a model for investigating both efficacy and immune response modulation in granulomatous infections.

Advanced Applications and Comparative Advantages

Amikacin’s profile as a bacterial protein synthesis inhibitor resistant to most aminoglycoside-modifying enzymes makes it a gold standard for antibiotic resistance research. In comparative studies, Amikacin consistently demonstrates superior activity against carbapenem-resistant K. pneumoniae and E. cloacae, offering advantages over legacy aminoglycosides where resistance genes are prevalent (protocol_best_practices).

Specifically, Amikacin’s resistance to inactivation by acetyltransferases—except for AAC (6')-I—enables its use in mapping resistance gene prevalence and functional studies on horizontal gene transfer. Its water solubility facilitates high-throughput screening and automated liquid handling workflows, reducing variability across replicates.

Building on insights from recent granuloma-targeting studies, Amikacin (BAY416651) is increasingly applied in advanced infection models where localized delivery and reduced systemic toxicity are priorities. This approach complements classic susceptibility testing, allowing researchers to bridge in vitro activity with in vivo relevance.

Comparative Interlinks: Extending the Knowledge Graph

To contextualize Amikacin’s strengths, several articles offer complementary perspectives:

• Molecular Mechanisms & Solubility Advantages: This article emphasizes Amikacin’s resistance to most modifying enzymes and its reproducibility in multidrug-resistant workflows, complementing the present article’s focus on applied protocol optimization.
• Molecular Insights & Resistance Dynamics: Extends the discussion to the genetic and mechanistic details underlying Amikacin’s activity and resistance patterns, providing a deeper foundation for those designing gene-driven resistance screens.
• Targeted Delivery & Granuloma Research: Directly complements the reference study, highlighting how Amikacin’s delivery into granulomatous tissue informs new strategies for localized therapy and resistance containment.

Troubleshooting and Optimization Tips

• Solubility issues: If cloudiness persists after reconstitution, ensure the water is sterile and at room temperature; apply gentle warming or ultrasonic agitation as described above. Avoid using DMSO or ethanol, as Amikacin is insoluble in these solvents (source: product_spec).
• Stock degradation: Always prepare fresh stock solutions, using aliquots promptly. Minimize freeze-thaw cycles to preserve antibiotic potency (source: product_spec).
• Resistance profiling: When unexpected resistance is observed, confirm the presence of aminoglycoside acetyltransferase AAC (6')-I via PCR or sequencing, as this enzyme can confer Amikacin resistance even in strains otherwise susceptible to aminoglycosides (molecular_insights).
• DC-based delivery validation: For cell-mediated delivery workflows, verify DC viability post-loading and use fluorescence microscopy or flow cytometry to confirm Amikacin-FITC uptake (source: reference).

Future Outlook: Implications for Resistance Research and Targeted Delivery

The targeted delivery model established by Montes-Worboys et al. is poised to shape the next generation of resistance research and anti-infective therapy development. By enabling high local concentrations of Amikacin at infection sites, this approach may permit dose reduction and mitigate systemic toxicity, a key concern in aminoglycoside therapy (reference). The integration of fluorescence-based tracking and immune cell-mediated delivery offers a dual advantage: precise pharmacokinetic mapping and the ability to interrogate immune-modulatory effects in vivo.

As research advances, Amikacin (BAY416651) will continue to serve as a cornerstone compound for dissecting antibiotic resistance, especially in settings where classical in vitro assays must be complemented with physiologically relevant infection models. The workflow innovations highlighted here—supported by APExBIO’s commitment to quality and reproducibility—set the stage for more effective study designs and translational discoveries in the fight against multidrug-resistant infections.

For detailed product specifications and ordering information, visit the Amikacin (BAY416651) Aminoglycoside Antibiotic page at APExBIO.